LAMF Global Ventures Corp. I: management transactions · United States · SEC (Form 4)

About LAMF Global Ventures Corp. I

LAMF Global Ventures Corp. I is a U.S.-listed SPAC that trades on the NASDAQ in the United States. For French-speaking investors, it should be viewed less as an operating industrial company and more as a listed acquisition vehicle created to identify and merge with a target business. The company was incorporated as a Cayman Islands exempted company on July 20, 2021, and its principal executive offices were located in West Hollywood, California. Its original purpose was to complete a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. In its initial SEC filings, LAMF said it intended to focus on opportunities in media, entertainment and sports, as well as e-commerce and technology, leveraging the operating experience and network of its management team. That framing was an investment thesis rather than an operating product portfolio. Before the de-SPAC transaction, LAMF did not have recurring commercial operations in the way a traditional operating company does. The key turning point was the completion of its business combination with Nuvo Group on May 1, 2024. In the SEC materials, Nuvo is described as an FDA-cleared remote pregnancy monitoring platform. As a result, the economic profile of the listed entity shifted materially: investors now need to assess the post-transaction company rather than the legacy SPAC alone. From a competitive standpoint, the SPAC itself had no standalone product-market position. Its value depended on sponsor credibility, transaction execution, capital structure management, and the ability to close a business combination within regulatory deadlines. Geographically, the original platform was U.S.-anchored, with headquarters in West Hollywood, California, while the acquired business added an international dimension through Nuvo’s Israel-linked operations and corporate footprint. Recent milestones have therefore centered on the de-SPAC process: shareholder approval in April 2024, deadline extensions to support the closing, and the completed merger in early May 2024. For equity investors, the name now needs to be analyzed through the lens of a newly combined public company with exposure to digital health and pregnancy monitoring, rather than as a pure cash-shell SPAC. This matters for risk assessment, growth expectations, and competitive positioning on the NASDAQ in the United States.